Category: Clinical Trials

A new clinical trial called ALSTARS is set to begin evaluating COYA 302, an investigational biologic therapy, as a potential treatment option for adults living with Amyotrophic Lateral Sclerosis (ALS). The study will be conducted at 20 to 25 sites across the United States and Canada, offering more patients access to cutting-edge research close to home.

COYA 302 combines two components: low dose interleukin-2 (LD IL-2) and DRL_AB, a biosimilar candidate for abatacept. Together, these are designed to work through a dual immunomodulatory mechanism, aiming to boost the anti-inflammatory activity of regulatory T cells while also calming inflammation driven by activated monocytes and macrophages. This approach reflects a growing scientific interest in addressing the immune and inflammatory components that may contribute to ALS progression.

The trial is structured thoughtfully, with participants randomly assigned to one of two COYA 302 dosing regimens or a placebo group during an initial 24-week double-blind period. Importantly, those who complete this phase will have the opportunity to continue into a 24-week extension period where they will receive one of the active COYA 302 regimens, giving more participants a chance to experience the investigational therapy over time.

Researchers will track meaningful, well-established measures of ALS progression, including the ALS Functional Rating Scale-Revised (ALSFRS-R), neurofilament light chain levels, maximal inspiratory pressure, and slow vital capacity. These outcome measures are widely used in ALS research and should provide valuable insight into whether COYA 302 can meaningfully impact disease trajectory, in addition to standard safety monitoring throughout the study.

For the ALS community, every new well-designed clinical trial represents a step forward. ALS remains a challenging condition with limited treatment options, and studies like ALSTARS that explore novel immunomodulatory approaches offer hope for expanding the therapeutic toolkit available to patients and clinicians. As enrollment moves forward across multiple sites, the coming months and years of data collection will help clarify whether this combination therapy can offer real benefit to those affected by this disease.

This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Study of COYA 302 for the Treatment of ALS

Eli Lilly has announced plans to seek FDA approval for retatrutide, an investigational peptide designed to target three key metabolic hormone receptors simultaneously, based on encouraging new clinical trial data. The move marks a significant step forward in the growing field of peptide-based therapies for weight management and metabolic health.

Retatrutide belongs to a novel class of compounds that act on GIP, GLP-1, and glucagon receptors together, an approach researchers believe may offer more comprehensive metabolic benefits than therapies that target a single pathway. The peptide has been closely watched by the scientific community as one of the more advanced multi-receptor candidates in development, building on the momentum of earlier GLP-1-based treatments that have already reshaped obesity care.

The decision to move toward regulatory submission reflects growing confidence in the drug’s data package, suggesting that the compound has performed well enough in trials to support a formal review by health authorities. For patients and clinicians, an FDA submission is a meaningful milestone, representing the transition from research-stage development to the possibility of a new treatment option becoming available under medical supervision.

This development is part of a broader wave of innovation in peptide therapeutics, where multi-target designs are increasingly seen as a way to potentially improve outcomes for people managing obesity and related metabolic conditions. If approved, retatrutide would add to a growing toolkit of peptide-based options that give physicians more ways to tailor treatment to individual patient needs.

While the regulatory process still lies ahead, the announcement underscores the pace at which peptide science is advancing and highlights the continued investment from major pharmaceutical companies in this promising area of medicine. As always, any new therapy would become available only through appropriate medical channels following regulatory review.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Lilly, with new data, to seek FDA approval of obesity drug retatrutide – BioPharma Dive

Researchers have launched a promising new phase III clinical trial designed to explore whether combining two targeted therapies—cetuximab and pembrolizumab—can offer better outcomes for patients facing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This large-scale study represents an important step forward in the ongoing effort to improve treatment options for patients whose cancer has returned or spread after previous therapy.

Pembrolizumab, an immunotherapy drug, is already a standard treatment that helps the immune system recognize and attack tumor cells. The new trial will test whether adding cetuximab, a monoclonal antibody that targets the EGFR protein found on many tumor cells, can enhance these effects. By blocking EGFR signaling, cetuximab may help slow tumor cell growth, potentially working in tandem with pembrolizumab’s immune-boosting properties to create a more powerful combined treatment approach.

What makes this trial particularly encouraging is its focus on a patient population that often faces limited treatment options after their cancer has recurred or spread. Head and neck cancers can be especially challenging to treat once they return, so any research aimed at expanding and improving therapeutic combinations offers real hope for better quality of life and outcomes for these patients.

This phase III design means the trial is a significant, well-structured study capable of generating robust data that could shape future treatment guidelines if the combination proves more effective than pembrolizumab alone. The scientific rationale—pairing an EGFR-targeting antibody with an immune checkpoint inhibitor—reflects a broader trend in oncology toward combination therapies that attack cancer through multiple mechanisms simultaneously.

As this trial progresses, the oncology community will be watching closely to see whether this combination can meaningfully improve outcomes for patients with recurrent or metastatic HNSCC. Trials like this one are essential building blocks in the continual refinement of cancer care, and their careful, rigorous design offers a path toward evidence-based improvements in treatment. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

A newly launched clinical trial is set to bring more clarity to how doctors treat one of the toughest bloodstream infections in modern medicine: methicillin-resistant Staphylococcus aureus, or MRSA. The open-label, randomized controlled trial will directly compare daptomycin, a cyclic lipopeptide antibiotic, with vancomycin, the two most commonly used therapies for this serious infection.

What makes this study particularly encouraging is its scale and structure. It is registered as an approved sub-study of the Staphylococcus aureus Network Adaptive Platform (SNAP) trial, a large international collaborative effort designed to continuously generate high-quality evidence on how best to treat S. aureus infections. By embedding this comparison within an adaptive platform trial, researchers can efficiently gather robust data while maintaining rigorous scientific standards, potentially accelerating the pace at which clinicians receive actionable answers.

Daptomycin, a naturally derived cyclic lipopeptide, works differently than traditional antibiotics like vancomycin, targeting bacterial cell membranes in a way that has made it a valuable tool against resistant strains. Head-to-head comparisons like this one help physicians understand not just whether a therapy works, but how it performs relative to established alternatives in real-world clinical settings. For patients facing MRSA bacteremia, a condition that can be life-threatening and challenging to treat, having more precise, evidence-based guidance on therapy selection could meaningfully improve outcomes.

This kind of comparative effectiveness research reflects the ongoing progress in peptide-based and peptide-adjacent therapeutics within infectious disease medicine. As resistant bacterial strains continue to pose challenges worldwide, trials like this one demonstrate the medical community’s commitment to refining and optimizing the tools already available, rather than simply accepting current standards of care as final. Better data on how these therapies compare could help clinicians make more confident, personalized decisions for patients with serious infections.

As the SNAP trial platform continues to expand its investigations, findings from this sub-study may offer valuable insights not only for MRSA treatment protocols but also for how adaptive trial designs can be used to answer pressing clinical questions more efficiently. This is a promising step toward more informed, evidence-driven care for a difficult-to-treat infection.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

A new peptide-based therapy called retatrutide is generating excitement in the medical community after clinical trial participants achieved weight loss of up to 30% of their body weight—results that rival those typically seen only with bariatric surgery. According to reporting from UCHealth, this milestone marks one of the most significant advances yet in the rapidly evolving field of weight-management medications.

Retatrutide works by targeting multiple hormone receptors involved in appetite regulation and metabolism, building on the mechanisms that have made earlier GLP-1-based treatments successful. By acting on additional pathways, researchers believe the drug may offer even greater benefits for people struggling with obesity, a condition linked to numerous chronic health issues including diabetes, heart disease, and joint problems.

What makes these findings especially encouraging is the possibility of achieving surgery-level results through a non-invasive treatment. For patients who are not candidates for bariatric surgery, or who wish to avoid its risks and recovery time, a highly effective medication could represent a life-changing alternative. Researchers and clinicians note that having multiple effective options allows doctors to better tailor treatment plans to individual patient needs and preferences.

The development of retatrutide reflects the broader momentum in peptide-based therapeutics, where scientists continue to refine and improve upon earlier breakthroughs. As more data emerges from ongoing trials, researchers will be watching closely to understand long-term safety, durability of results, and how this treatment compares with existing options over extended use.

While still in the research and development pipeline, retatrutide’s early results offer a hopeful glimpse into the future of obesity treatment—one where significant, sustained weight loss may be achievable without surgery for a growing number of patients. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Retatrutide, the newest weight-loss drug, helped people lose 30% of body weight, on par with weight-loss surgery – UCHealth

In an encouraging development for the growing field of GLP-1 peptide therapeutics, biopharmaceutical company Altimmune has reported that its GLP-1-based drug candidate reduced heavy drinking episodes among participants in a clinical trial for alcohol use disorder (AUD). The findings add to a growing body of evidence suggesting that GLP-1 receptor agonists, originally developed for diabetes and weight management, may have applications well beyond metabolic health.

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone that influences appetite, blood sugar regulation, and reward pathways in the brain. Researchers have increasingly explored whether drugs that mimic this hormone could also help curb compulsive behaviors, including excessive alcohol consumption. This latest trial result lends support to that hypothesis, showing a measurable decrease in heavy drinking days among those who received the treatment compared to baseline levels.

Alcohol use disorder affects millions of people worldwide, and current treatment options remain limited in both scope and effectiveness. A therapy rooted in peptide science that could offer a new mechanism of action would represent a meaningful addition to the treatment landscape. Because GLP-1 drugs are already well-studied for their safety profiles in diabetes and obesity care, any successful expansion into AUD treatment could potentially benefit from a smoother path through further clinical development.

For the peptide research community, this trial underscores the versatility of GLP-1-based compounds and highlights how a single class of molecules can yield benefits across seemingly unrelated health conditions. It also reflects a broader trend in medicine: leveraging the body’s own signaling systems, mimicked through engineered peptides, to address complex behavioral and physiological challenges in a targeted way.

While these results are still early-stage and further studies will be needed to confirm long-term efficacy and safety, the trial represents a hopeful step forward for individuals seeking new options to manage alcohol use disorder. As research continues, True North Labs will keep following developments in this space with interest.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol Use Disorder Trial – MedCity News